Early evidence suggests a new PET imaging agent from California-based Attralus can help evaluate all varieties of systemic cardiac amyloidosis. It has now been granted the FDA's breakthrough therapy designation. 

Bharath Krishnamurthy, director of health policy and analytics, American Hospital Association, explains factors leading to the economic instability of the U.S. healthcare system. 

Telix Pharmaceuticals Ltd. announced the news on July 31, with the decision applying to its TLX250-CDx investigational agent for clear cell renal cell carcinoma (brand name Zircaix). 

The AMA applauded the Texas Medical Association for defeating dozens of scope of practice creep bills in the Texas legislature this year.

CVRx has now received improved outpatient and inpatient reimbursements for its implantable heart failure device in the last 12 months. The company's president says these updates will help more patients gain access to the Barostim technology. 

Bharath Krishnamurthy, a director of health policy and analytics at the American Hospital Association, explains the financial impact of current healthcare staffing shortages.

The drugmaker argues that the FDA's recent approval of a generic version of Entresto should not be allowed for multiple reasons. Novartis sent multiple requests to the agency hoping to stop the approval, but the FDA denied each one. 

Despite raging inflation and rising staff costs, the conversion factor is the lowest it’s been since 1993, Richard Heller, MD, MBA, wrote for MedPage Today.